Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584062 | 0.87 | GAA (0.52) | CHRNA7GAAHTR3EHTR3BHTR3A | |
| SCHEMBL4152261 | 0.80 | CHRNA7 (0.65) | CHRNA7GAAHTR3EHTR3BHTR3A | |
| SCHEMBL12127600 | 0.79 | KMT2A (0.52) | CHRNA7GAAHTR3EHTR3BHTR3A | |
| SCHEMBL9687625 | 0.77 | GAA (0.37) | GAATSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL10729081 | 0.76 | RAB9A (0.48) | GAATSHRAPOBEC3AAPOBEC3GKMT2A | |
| SCHEMBL21164349 | 0.76 | CHRNA7 (0.56) | CHRNA7GAAHTR3EHTR3BHTR3A | |
| SCHEMBL18612809 | 0.76 | CHRNA7 (0.56) | CHRNA7GAAHTR3EHTR3BHTR3A | |
| SCHEMBL18608149 | 0.75 | CHRNA7 (0.59) | CHRNA7GAAHTR3EHTR3BHTR3A | |
| SCHEMBL18607904 | 0.75 | CHRNA7 (0.59) | CHRNA7GAAHTR3EHTR3BHTR3A | |
| SCHEMBL904139 | 0.74 | CHRNA7 (0.62) | CHRNA7GAAHTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2009-07-09 | — | — | US | disclosed |
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2009-07-09 | — | — | US | disclosed |
| EP-2006284-A1 | DICYCLOOCTANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | DPP4, DPP7, DPP8 | CHRNA7 4105/4885GAA 182/4885HTR3E 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.